InVitae Corp (NASDAQ:NVTA) – Research analysts at William Blair raised their FY2017 earnings estimates for InVitae Corp in a report released on Tuesday. William Blair analyst A. Murphy now anticipates that the medical research company will post earnings of ($2.39) per share for the year, up from their previous forecast of ($2.48). William Blair also issued estimates for InVitae Corp’s FY2018 earnings at ($1.67) EPS.

Several other research analysts also recently commented on NVTA. Zacks Investment Research raised shares of InVitae Corp from a “sell” rating to a “hold” rating in a report on Friday, August 11th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $15.00 price target (up from $14.00) on shares of InVitae Corp in a report on Wednesday, August 9th. BidaskClub downgraded shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine raised shares of InVitae Corp from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $12.94.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Forecast for InVitae Corp (NVTA) Issued By William Blair” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/18/fy2017-earnings-forecast-for-invitae-corp-nvta-issued-by-william-blair.html.

InVitae Corp (NVTA) opened at 9.55 on Friday. The firm’s market capitalization is $415.85 million. The stock’s 50 day moving average is $9.56 and its 200 day moving average is $9.82. InVitae Corp has a one year low of $5.76 and a one year high of $11.88.

InVitae Corp (NASDAQ:NVTA) last announced its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.02. InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The firm had revenue of $14.34 million for the quarter, compared to analyst estimates of $13.31 million. During the same quarter in the prior year, the firm earned ($0.77) earnings per share. The firm’s revenue for the quarter was up 157.0% on a year-over-year basis.

Several hedge funds have recently bought and sold shares of NVTA. Renaissance Technologies LLC bought a new stake in InVitae Corp during the fourth quarter worth about $879,000. HighTower Advisors LLC increased its stake in InVitae Corp by 11.9% in the first quarter. HighTower Advisors LLC now owns 252,744 shares of the medical research company’s stock worth $2,792,000 after buying an additional 26,787 shares in the last quarter. Donald L. Hagan LLC increased its stake in InVitae Corp by 30.0% in the second quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after buying an additional 3,000 shares in the last quarter. State Street Corp increased its stake in InVitae Corp by 9.4% in the fourth quarter. State Street Corp now owns 338,514 shares of the medical research company’s stock worth $2,688,000 after buying an additional 29,017 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in InVitae Corp during the first quarter worth about $302,000.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Earnings History and Estimates for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.